Tsumura & Co.
Stock Price Chart
2026/07/16 UpdatedPrice Trend
2026/07/16 UpdatedPrice & Trading Details
2026/07/16 UpdatedPRICE
TRADING
Analyst Recommendations 4 analysts
Updated 2026/07/01Earnings Calendar
Updated 2026/07/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/02/05 | ¥90.93 | ¥142.95 | +57.2% |
| 2025/11/09 | ¥90.93 | ¥108.49 | +19.3% |
| 2025/08/04 | ¥90.93 | ¥58.16 | -36.0% |
| 2025/05/11 | ¥124.55 | ¥77.27 | -38.0% |
Shareholder Composition
Updated 2026/07/01Major Holders
Updated 2026/07/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
|
1.2M | +43.05% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
972.0K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
641.7K | +0.98% | |
|
Victory Portfolios-Victory Trivalent International Small-Cap Fund
|
541.2K | -0.07% | |
|
Bridge Builder Trust-Bridge Builder International Equity Fund
|
445.2K | -2.26% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
411.5K | 0.00% |
Dividend History
Updated 2026/07/12| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥79 | -41.9% |
| 2025 | ¥136 | +15.3% |
| 2024 | ¥118 | +76.1% |
| 2023 | ¥67 | +4.7% |
| 2022 | ¥64 | - |
Financial Performance
2026/07/12 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥129,546M | ¥140,043M | ¥150,845M | ¥181,093M |
| Gross Profit | ¥66,465M | ¥68,281M | ¥68,816M | ¥90,583M |
| Operating Income | ¥22,377M | ¥20,916M | ¥20,017M | ¥40,125M |
| Pretax Income | ¥25,736M | ¥23,274M | ¥24,066M | ¥46,077M |
| Net Income | ¥18,836M | ¥16,482M | ¥16,707M | ¥32,428M |
| EPS | ¥246.21 | ¥215.63 | ¥219.83 | ¥427.15 |
| Operating Margin | 17.27% | 14.94% | 13.27% | 22.16% |
| Balance Sheet | ||||
| Total Assets | ¥350,981M | ¥396,813M | ¥428,254M | ¥464,380M |
| Total Equity | ¥239,769M | ¥252,045M | ¥270,801M | ¥300,528M |
| Total Liabilities | ¥111,212M | ¥144,768M | ¥157,453M | ¥163,852M |
| Cash | ¥67,552M | ¥94,752M | ¥78,075M | ¥73,227M |
| Interest-bearing Debt | ¥49,690M | ¥79,690M | ¥79,690M | ¥70,336M |
| Equity Ratio | 68.31% | 63.52% | 63.23% | 64.72% |
| D/E Ratio | 0.21 | 0.32 | 0.29 | 0.23 |
| Cash Flow | ||||
| Operating CF | ¥21,314M | ¥16,452M | ¥5,608M | ¥33,823M |
| Investing CF | -¥9,111M | -¥15,493M | -¥19,351M | -¥24,974M |
| Financing CF | -¥8,181M | ¥24,423M | -¥4,417M | -¥19,871M |
| Free CF | ¥10,727M | ¥1,744M | -¥14,449M | ¥4,029M |
| Efficiency | ||||
| ROE | 7.86% | 6.54% | 6.17% | 10.79% |
| ROA | 5.37% | 4.15% | 3.90% | 6.98% |
Latest IR Information
-
[Tsumura] Announces Executive Change | June 2026
Tsumura Co., Ltd. announced a change in the position of the President and Representative Director, Kei Sugii, scheduled for June 26, 2026, aiming to strengthen management control and accelerate decision-making.
Read more -
【Tsumura】Dividend Increase and Earnings Revision｜May 2026
Tsumura has approved an increase in the dividend for the fiscal year ending March 2026 to 79 yen per share, with an annual dividend of 147 yen. This increase is driven by higher net profit in 2025, maintaining a payout...
Read more -
【Tsumura】2026 Fiscal Year Quarterly Earnings Supplementary Materials | Sales of ¥181 billion (up 6.4% YoY)
According to Tsumura's FY2026 quarterly earnings supplementary materials, sales reached ¥181 billion (up 6.4% YoY), with operating and net income also trending upward. Segments show strong performance domestically and in China.
Read more -
【Tsumura】2026 Earnings Results | Sales: 192.6 billion yen (+6.4%)
Tsumura achieved sales of 192.6 billion yen (up 6.4% YoY) in the fiscal year ending March 2026, driven by the recovery from infectious disease outbreaks and expansion of the China business. Operating profit decreased to 3.52 billion yen (△12.2%), and...
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥4,400
Rating Score: 2.75 (Based on 4 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Tsumura & Co. engages in the production and sale of Kampo extract intermediates and granular Kampo formulations in Japan and internationally. The company offers products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation and hemorrhoids, as well as body aches, children's sickness, stress, urinary problems, and cold, cough, and nasal and throat inflammation symptoms. It also offers over-the-counter Kampo medicines. The company was founded in 1893 and is headquartered in Tokyo, Japan.
